Emergent Biosolutions Inc

EBSNYSE · USD
5.79USD0.00 (-1.70%)
1027

Emergent Biosolutions Inc (EBS) Covered Calls

Emergent Biosolutions Inc trades in the Drug Manufacturers - Specialty & Generic industry with an IV Rank of 4.76%, low versus the past year. EBS's highest covered call setup is the $9.00 strike expiring Jan 15, 2027, sorted by theoretical annualized return. It's 55.44% out of the money with 63 days to expiration, a 56.30% return until expiration, and a 326.21% theoretical annualized return. Across the setups shown, annualized returns run from 103.90% to 326.21% at strikes between $6.00 and $14.00, with 7 to 216 days to expiration, as of Nov 13, 2026.

Read more

Running EBS covered calls helps you generate income from Emergent Biosolutions Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best EBS covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If EBS stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling EBS covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given EBS covered call is worth writing.

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate.

2027-01-15639.0055.440.050.20326.0056.30326.21-0.86+0.142560.15
2027-06-1721614.00141.800.100.40831.00143.52242.53-1.73+0.1600.30
2026-12-18357.0020.900.100.20131.0022.63235.95-1.73+0.23710.10
2026-11-2076.003.630.050.3026.004.49234.15-0.86+0.40520.25
2027-06-1721612.00107.250.050.55626.00108.12182.70-0.86+0.2000.50
2027-03-191269.0055.440.150.25336.0058.03168.11-2.59+0.19140.10
2027-06-1721611.0089.980.100.50531.0091.71154.97-1.73+0.2100.40
2027-01-15637.0020.900.100.40131.0022.63131.08-1.73+0.291,1390.30
2027-06-1721610.0072.710.200.50441.0076.17128.71-3.45+0.2440.30
2027-06-172169.0055.440.351.00356.0061.49103.90-6.04+0.3700.65

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

  • IndustryDrug Manufacturers - Specialty & Generic
  • SectorHealthcare
  • IV Rank4.76% Low
  • Market cap (M$)298
  • 52 weeks high-58.82%
  • 52 weeks low32.80%
  • Analyst recommendationBuy
    2.33
  • Target price$10.00
    72.71% above the current stock price
  • Dividend—
  • Payout ratio0.00%
  • Earnings date2026-11-02
  • P/E—
  • Future P/E5.53
  • EPS (ttm)-5.10
  • EPS growth next 5 years0.83%

As of Nov 13, 2026